AN2 Therapeutics, Inc.
NASDAQ:ANTX
1.08 (USD) • At close October 22, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0.04 | 0 | 0.021 | 0.019 | 0.02 | 0.02 | 0.019 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0.04 | 0 | -0.021 | -0.019 | -0.02 | -0.02 | -0.019 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 12.149 | 14.655 | 14.919 | 14.429 | 13.538 | 11.985 | 8.752 | 8.428 | 6.698 | 5.633 | 5.812 | 5.345 | 4.1 | 1.649 |
| General & Administrative Expenses
| 3.731 | 3.641 | 3.896 | 3.751 | 3.063 | 4.054 | 3.724 | 3.342 | 3.635 | 2.05 | 1.782 | 1.587 | 0.898 | 0.401 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.731 | 3.641 | 3.896 | 3.751 | 3.063 | 4.054 | 3.724 | 3.342 | 3.635 | 2.05 | 1.782 | 1.587 | 0.898 | 0.401 |
| Other Expenses
| 1.445 | 1.679 | 1.917 | 1.473 | 0.797 | 0.716 | 0.004 | -0.035 | -0.015 | 0.001 | 0.022 | -0.036 | -0.024 | 0 |
| Operating Expenses
| 15.88 | 18.296 | 18.815 | 18.18 | 16.601 | 16.039 | 12.476 | 11.77 | 10.333 | 7.683 | 7.594 | 6.932 | 4.998 | 2.05 |
| Operating Income
| -15.88 | -18.296 | -18.815 | -18.18 | -16.601 | -16.039 | -12.476 | -11.77 | -10.333 | -7.628 | -7.594 | -6.932 | -4.998 | -2.05 |
| Operating Income Ratio
| 0 | 0 | -235.188 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.445 | 1.679 | 1.917 | 1.473 | 0.797 | 0.716 | 0.634 | 0.431 | 0.213 | -0.027 | 0.022 | -0.036 | -0.024 | 0.002 |
| Income Before Tax
| -14.435 | -16.617 | -16.898 | -16.707 | -15.804 | -15.323 | -11.842 | -11.339 | -10.12 | -7.655 | -7.545 | -6.943 | -5.007 | -2.048 |
| Income Before Tax Ratio
| 0 | 0 | -211.225 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -15.88 | -18.296 | -0.019 | -0.018 | -0.021 | -0.716 | 0.945 | -0.431 | -0.441 | -0.055 | -7.621 | -6.957 | -5.013 | -2.05 |
| Net Income
| -14.435 | -16.617 | -16.898 | -16.707 | -15.804 | -14.607 | -12.787 | -10.908 | -9.679 | -7.6 | -7.545 | -6.943 | -5.007 | -2.048 |
| Net Income Ratio
| 0 | 0 | -211.225 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.48 | -0.56 | -0.57 | -0.65 | -0.81 | -0.75 | -0.66 | -0.56 | -0.5 | -0.4 | -0.42 | -0.49 | -0.36 | -0.15 |
| EPS Diluted
| -0.48 | -0.56 | -0.57 | -0.65 | -0.81 | -0.75 | -0.66 | -0.56 | -0.5 | -0.4 | -0.42 | -0.49 | -0.36 | -0.15 |
| EBITDA
| -15.88 | -18.296 | -18.815 | -18.18 | -16.601 | -16.039 | -12.476 | -11.77 | -10.333 | -7.683 | -7.594 | -6.932 | -4.998 | -2.05 |
| EBITDA Ratio
| 0 | 0 | -235.188 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |